Skip to main content
Premium Trial:

Request an Annual Quote

Phenomenex, Tecan Ink Marketing Deal for SPE Sample Prep Solutions

NEW YORK (GenomeWeb) – Phenomenex and Tecan Group on Tuesday announced a co-marketing agreement for Phenomenex's automated solid phase extraction sample preparation solutions. 

The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations. The solution, they said, is geared to high-throughput customers in pharmaceutical research, and clinical and food testing using mass spectrometry methods. 

Tecan will provide the instruments and automation support, while Phenomenex will provide the extraction chemistries. It also will work with the PhenoLogix group, a full-service analytical support laboratory within Phenomenex, on applications and method development. 

The firms said that Phenomenex Strata and Strata-X SPE sorbents remove unwanted contaminants, such as phospholipids, and are available in a variety of selectivities to cover a range of analytes. Performing solid phase extraction on Tecan's instruments in combination with optimized conditions from PhenoLogix "will decrease implementation efforts in the lab, increase throughput while reducing human error, and enable sample traceability for regulated environments," Phenomenex and Tecan said. 

Tecan Head of Clinical Diagnostics James O' Brien said in a statement that the agreement will enable Tecan to expand its reach in the high-volume solid phase extraction space. 

"The experts at Phenomenex and PhenoLogix have enhanced our knowledge of chromatography and enabled us to bring to market a product for mid- to high-throughput laboratories that increases the [return on investments] of their high-capital investment in mass spectrometry detection systems," O' Brien said.  

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more